Financials data is unavailable for this security.
View more
Year on year Valiant Laboratories Ltd 's revenues fell -45.48%from 3.34bn to 1.82bn. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a -98.90% reduction in net income from 289.98m to 3.20m.
| Gross margin | 3.07% |
|---|---|
| Net profit margin | -2.98% |
| Operating margin | -11.13% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Valiant Laboratories Ltd increased its cash reserves by 828.84%, or 104.57m. Cash Flow from Financing totalled 1.52bn or 83.74% of revenues. In addition the company generated 18.85m in cash from operations while cash used for investing totalled 1.44bn.
| Cash flow per share | -0.6292 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items dropped -99.06%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -- |
